Tigemonam is a monobactam, a novel orally administered monobactam that protects against gram-negative aerobic bacterial pathogens and is at least as active against clinical isolates of Enterobacteriaceae as amitraz or carmonan (MIC90: 0.06-16 mg/l). [3]

Tigemonam (0.25 mg/L) inhibits 90% of Escherichia coli, Klebsiella spp., Proteus spp., Salmonella spp., Haemophilus influenzae, and Branhamella catarrhalis. The MIC90 is 16 mg/L for Enterobacter spp. and 4 mg/L for Citrobacter. Pseudomonas aeruginosa is resistant to tigemonam but susceptible to aztreonam. Tigemonam shows minimal inoculum dependence, between 10^2 and 10^6 cfu per spot [1].

Tigemonam demonstrates potent efficacy against a range of bacterial strains, including E. coli SC 12199, Escherichia coli SC 8294, Salmonella schottmulleri SC 3850, Proteus mirabilis SC 9575, Providencia rettgeri SC 8217, Klebsiella pneumoniae SC 12216, Serratia marcescens SC 9782, Enterobacter cloacae SC 11078, and Haemophilus influenzae SC 10556, achieving ED50 values of 1.5 mg/kg, 1.4 mg/kg, 0.7 mg/kg, 0.3 mg/kg, 0.2 mg/kg, 0.9 mg/kg, 0.5 mg/kg, 3.9 mg/kg, and 1.8 mg/kg respectively in mice.